Compare · FMS vs LSTA
FMS vs LSTA
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. FMS focuses on Misc Health and Biotechnology Services, while LSTA focuses on Biotechnology: Pharmaceutical Preparations.
- FMS is the larger of the two at $12.31B, about 941.3x LSTA ($13.1M).
- LSTA has been more active in the news (9 items in the past 4 weeks vs 8 for FMS).
- FMS has more recent analyst coverage (25 ratings vs 0 for LSTA).
- Company
- Fresenius Medical Care AG
- Lisata Therapeutics Inc.
- Price
- -
- -
- Market cap
- $12.31B
- $13.1M
- 1M return
- -
- +17.45%
- 1Y return
- -
- -41.27%
- Industry
- Misc Health and Biotechnology Services
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 9
- Recent ratings
- 25
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by Barclays
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook
- Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
- Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- SEC Form S-3 filed by Lisata Therapeutics Inc.
- SEC Form S-8 filed by Lisata Therapeutics Inc.
- Amendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form DEFA14A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
- SEC Form DEF 14A filed by Lisata Therapeutics Inc.
- SEC Form 3 filed by Lisata Therapeutics Inc.